StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
The data demonstrates improved efficacy compared to existing treatments, historically positive trials boost stock prices.
What happened, with direct paths to the underlying reporting
Arcus reported promising casdatifan data for metastatic ccRCC. Confirmed overall response rate of 31% across 121 patients. Median progression-free survival reached 12.2 months. Data showed high patient disease control at 81%. Stock increased by 7.87%, trading at $14.40.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.